<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03546400</url>
  </required_header>
  <id_info>
    <org_study_id>B7491020</org_study_id>
    <nct_id>NCT03546400</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.</brief_title>
  <official_title>A Phase 4, Open-label, Safety, Tolerability And Pharmacokinetic Study Of Methylphenidate Hydrochloride (Hcl) Extended Release Chewable Tablet (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (Adhd)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      2-week open-label safety, tolerability and pharmacokinetic study of methylphenidate HCl ERCT
      in 4-5 year old children with ADHD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 4, Open-label, Safety, Tolerability And Pharmacokinetic Study Of methylphenidate
      Hydrochloride (HCl) Extended Release Chewable Tablets (ERCT) In 4-5 Year Old Children With
      Attention Deficit Hyperactivity Disorder (ADHD)
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was cancelled prior to the enrollment of any participants.
  </why_stopped>
  <start_date type="Anticipated">September 25, 2018</start_date>
  <completion_date type="Anticipated">December 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK parameter-Tmax</measure>
    <time_frame>2 weeks</time_frame>
    <description>PK profile of methylphenidate following a single oral dose of 30 mg methylphenidate HCl ERCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter- Cmax</measure>
    <time_frame>2 weeks</time_frame>
    <description>PK profile of methylphenidate following a single oral dose of 30 mg methylphenidate HCl ERCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter- AUClast</measure>
    <time_frame>2 weeks</time_frame>
    <description>PK profile of methylphenidate following a single oral dose of 30 mg methylphenidate HCl ERCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter-AUC0-2</measure>
    <time_frame>2 weeks</time_frame>
    <description>PK profile of methylphenidate following a single oral dose of 30 mg methylphenidate HCl ERCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter-AUC2-6</measure>
    <time_frame>2 weeks</time_frame>
    <description>PK profile of methylphenidate following a single oral dose of 30 mg methylphenidate HCl ERCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter-AUC6-24</measure>
    <time_frame>2 weeks</time_frame>
    <description>PK profile of methylphenidate following a single oral dose of 30 mg methylphenidate HCl ERCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter-AUCinf</measure>
    <time_frame>2 weeks</time_frame>
    <description>PK profile of methylphenidate following a single oral dose of 30 mg methylphenidate HCl ERCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter- t1/2</measure>
    <time_frame>2 weeks</time_frame>
    <description>PK profile of methylphenidate following a single oral dose of 30 mg methylphenidate HCl ERCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter-CL/F</measure>
    <time_frame>2 weeks</time_frame>
    <description>PK profile of methylphenidate following a single oral dose of 30 mg methylphenidate HCl ERCT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter-Vz/F</measure>
    <time_frame>2 weeks</time_frame>
    <description>PK profile of methylphenidate following a single oral dose of 30 mg methylphenidate HCl ERCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of treatment emergent adverse events (safety and tolerability)</measure>
    <time_frame>2 weeks</time_frame>
    <description>incidence of treatment emergent adverse events (safety and tolerability)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>methylphenidate HCl ERCT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>methylphenidate HCl ERCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate HCl ERCT</intervention_name>
    <description>methylphenidate HCl ERCT</description>
    <arm_group_label>methylphenidate HCl ERCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female child 4-5 years of age at screening.

          2. Signed and dated informed consent provided by the subject's parent/legal and assent of
             the child (as applicable)

          3. Meets DSM-5 criteria for ADHD based on the K-SADS-PL.

          4. ADHD RS-IV Preschool—Home Version score at Screening and Baseline &gt;/= 90th percentile
             for gender and age in &gt;/=1 of the following: hyperactive-impulsive subscale,
             inattentive subscale, or total score.

          5. Peabody Picture Vocabulary Test 4 (PPVT—4)Standard Score &gt;/=70.

          6. Child Global Assessment Scale (CGAS) score &lt;/= 55.

          7. History of an adequate course of non medication treatment for ADHD based on
             investigator judgment or, where such treatments are not available, the severity of the
             subject's ADHD symptoms are such that medication treatment is deemed necessary by the
             investigator.

        Exclusion Criteria:

          1. Treated with atomoxetine within 30 days prior to the Baseline.

          2. Received any investigational products or devices within 30 days prior to the Baseline
             visit.

          3. History of stimulant nonresponse, intolerability or hypersensitivity to any dose of
             methylphenidate or other stimulant.If a subject has a known allergy to D&amp;C red #30,
             he/she should not be enrolled in the study.

          4. An intelligence quotient (IQ) &lt;70.

          5. History of acute or chronic medical or psychiatric condition or cardiac or laboratory
             abnormality.

          6. Less than 5th percentile for height or weight at Screening.

          7. History of recent clinically significant self-harming behaviors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>48 Months</minimum_age>
    <maximum_age>69 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7491020&amp;StudyName=An+Open+Label+Pharmacokinetic+Study+Of+Methylphenidate+Extended+Release+Chewable+Tablet+%28erct%29+In+Adhd+Patients+Aged+4-5+Years+Old</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7491020&amp;StudyName=A+Phase+4%2C+Open+Label%2C+Safety%2C+Tolerability+And+Pharmacokinetic+Study+Of+Quillichew+Extended+Release+Chewable+Tablets+%28methylphenidate+Hcl+Extended+Release+Chewable+Tablets+%5Berct%5D%29+In+4+5+Year+Old+Children+With+Attention+Deficit+Hyperactivity+Disorder+%28adhd%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7491020&amp;StudyName=A+Phase+4%2C+Open-label%2C+Safety%2C+Tolerability+And+Pharmacokinetic+Study+Of+Quillichew+%28methylphenidate+Hydrochloride+%28hcl%29%29+Extended+Release+Chewable+Tablets+%28erct%29+In+4+5+Year+Old+Children+With+Attention+Deficit+Hyperactivity+Disorder+%28adhd%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7491017&amp;StudyName=A+Multi-center%2C+Double-blind%2C+Randomized%2C+Placebo-controlled%2C+Parallel+Group+Study+Evaluating+The+Safety+And+Efficacy+Of+Quillivant+Xr+In+The+Treatment+Of+Pre-school+Aged+Children+With+Adhd</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7491017&amp;StudyName=A+Phase+4%2C+Double-blind%2C+Randomized%2C+Parallel+Group%2C+Placebo-controlled+Study+Of+The+Efficacy+And+Safety+Of+Quillichew+Extended+Release+Chewable+Tablets+%28methylphenidate+Hcl+Extended+Release+Chewable+Tablets+%28erct%29%29++In+4-5+Year+Old+Children+With+Attention+Deficit+Hyperactivity+Disorder+%28adhd%29.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7491017&amp;StudyName=A+Phase+4%2C+Double-blind%2C+Randomized%2C+Parallel+Group%2C+Placebo-controlled+Study+Of+The+Efficacy+And+Safety+Of+Quillichew+%28methylphenidate+Hydrochloride+%28hcl%29%29+Extended+Release+Chewable+Tablets+%28erct%29+In+4-5+Year+Old+Children+With+Attention+Deficit+Hyperactivity+Disorder+%28adhd%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7491020&amp;StudyName=A+Phase+4%2C+Open-label%2C+Safety%2C+Tolerability+And+Pharmacokinetic+Study+Of+Methylphenidate+Hydrochloride+%28hcl%29+Extended+Release+Chewable+Tablet+%28erct%29+In+4-5+Year+Old+Children+With+Attention+Deficit+Hyperactivity+Disorder+%28adhd%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

